In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries. This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA.
In September, AARP issued its latest Rx Price Watch report, which tracks price trends for prescription drugs that are widely used by older Americans. That report highlighted the problem of skyrocketing drug costs; it found that the retail prices for widely used drugs increased well above the rate of inflation, and that’s a troubling trend for Medicare beneficiaries.
This week on the podcast, we’re speaking with one of the authors of that report, Leigh Purvis, MPA. Purvis is the director of health services research at the AARP Public Policy Institute, where she leads a team of policy analysts and researchers who work on health care issues that are relevant to the population of Americans aged 50 or older.
We discussed the drug pricing report, the burden that older Americans face from high out-of-pocket costs, and possible policy solutions.
Read more about the AARP report, the White House Council of Economic Advisors report, and AARP’s Stop Rx Greed campaign.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.